The safety and efficacy of 5% Niacinamide cream for infraorbital hyperpigmentation
Article Sidebar
Main Article Content
บทคัดย่อ
Infraorbital hyperpigmentation becomes a significant concern in individual regardless of gender and age. The etiology of infraorbital hyperpigmentation is multifactorial including excessive pigmentation, periorbital volume loss, skin laxity and density of subcutaneous vasculature. Moreover, its management is quite challenging because multiple factors contribute this condition and choosing the appropriate treatment according to the causative factors. Among the causes, excessive pigmentation due to increased melanin is the most common factor. Niacinamide, one of the active forms of vitamin B3, possesses various properties such as skin lightening effect, anti-inflammatory, antioxidants and sebostatic effect. However, no clinical study that demonstrating the safety and efficacy of 5% Niacinamide cream for infraorbital area.
Article Details
อนุญาตภายใต้เงื่อนไข Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
• บทความทุกเรื่องได้รับการตรวจสอบทางวิชาการโดยผู้ทรงคุณวุฒิ จำนวน 3 ท่าน ต่อ 1 เรื่อง จากภายในและภายนอกวิทยาลัยบัณฑิตเอเซีย
• การตีพิมพ์และเผยแพร่ของวารสารวิทยาลัยบัณฑิตเอเซียนี้ เนื้อหาบทความ ทรรศนะและข้อคิดเห็นใด ๆ ในวารสารถือว่าเป็นของผู้เขียน โดยเฉพาะทางกองบรรณาธิการวารสาร หรือวิทยาลัยบัณฑิตเอเซีย ไม่จำเป็นต้องเห็นด้วย
เอกสารอ้างอิง
Bissett, D. L., Miyamoto, K., Sun, P., Li, J., & Berge, C. A. (2004). Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin1. International Journal of Cosmetic Science, 26(5); 231–238. https://doi.org/10.1111/j.1467-2494.2004.00228.
Bissett, D. L., Robinson, L. R., Raleigh, P. S., Miyamoto, K., Hakozaki, T., Li, J., & Kelm, G. R. (2009). Reduction in the appearance of facial hyperpigmentation by topical N -undecyl-10-enoyl-l-phenylalanine and its combination with niacinamide. Journal of Cosmetic Dermatology, 8(4); 260–266. https://doi.org/10.1111/j.1473-2165.2009.00470.
Chaidemenos, G. C. (2001). Tetracycline and niacinamide in the treatment of blistering skin diseases. Clinics in Dermatology, 19(6); 781–785. https://doi.org/10.1016/S0738-081X(00)00187-5.
Chen, A. C., & Damian, D. L. (2014). Nicotinamide and the skin: Nicotinamide and the skin. Australasian Journal of Dermatology, 55(3); 169–175. https://doi.org/10.1111/ajd.12163.
Friedmann, D. P., & Goldman, M. P. (2015). Dark Circles. Clinics in Plastic Surgery, 42(1); 33–50. https://doi.org/10.1016/j.cps.2014.08.007.
Hakozaki, T., Minwalla, L., Zhuang, J., Chhoa, M., Matsubara, A., Miyamoto, K., Greatens, A., Hillebrand, G. G., Bissett, D. L., & Boissy, R. E. (2002). The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. British Journal of Dermatology, 147(1); 20–31. https://doi.org/10.1046/j.1365-2133.2002.04834.
Imokawa, G., Miyagishi, M., & Yada, Y. (1995). Endothelin-1 as a New Melanogen: Coordinated Expression of Its Gene and the Tyrosinase Gene in UVB-Exposed Human Epidermis. Journal of Investigative Dermatology, 105(1); 32–37. https://doi.org/10.1111/1523-1747.ep12312500.
Lee, D. H., Oh, I. Y., Koo, K. T., Suk, J. M., Jung, S. W., Park, J. O., Kim, B. J., & Choi, Y. M. (2014). Reduction in facial hyperpigmentation after treatment with a combination of topical niacinamide and tranexamic acid: A randomized, double-blind, vehicle-controlled trial. Skin Research and Technology, 20(2); 208–212. https://doi.org/10.1111/srt.12107.
Nayak, C. S., Ansari, S. M. M., Salve, V., & Patil, S. (2019). Effectiveness of a combination of anti-pigmentary products in facial post-inflammatory hyperpigmentation. International Journal of Research in Dermatology, 6(1), 1. https://doi.org/10.18203/issn.2455-4529. IntJResDermatol20195199.
Rolfe, H. M. (2014). A review of nicotinamide: Treatment of skin diseases and potential side effects. Journal of Cosmetic Dermatology, 13(4); 324–328. https://doi.org/10.1111/jocd.12119.
Sawant, O., & Khan, T. (2020). Management of periorbital hyperpigmentation: An overview of nature‐based agents and alternative approaches. Dermatologic Therapy, 33(4). https://doi.org/10.1111/dth.13717
Seiberg, M. (2001). Keratinocyte-Melanocyte Interactions During Melanosome Transfer: Melanosome Transfer. Pigment Cell Research, 14(4); 236–242. https://doi.org/10.1034/j.1600-0749.2001.140402.
Surjana, D., Halliday, G. M., Martin, A. J., Moloney, F. J., & Damian, D. L. (2012). Oral Nicotinamide Reduces Actinic Keratoses in Phase II Double-Blinded Randomized Controlled Trials. Journal of Investigative Dermatology, 132(5); 1497–1500. https://doi.org/10.1038/jid.2011.459.
Wohlrab, J., & Kreft, D. (2014). Niacinamide—Mechanisms of Action and Its Topical Use in Dermatology. Skin Pharmacology and Physiology, 27(6); 311–315. https://doi.org/10.1159/000359974.
